

# TABLE OF CONTENTS

June 25, 2007

No. 2046

## BUSINESS

- 1 Teijin Pharma Aims at Entering Home Health Care Business in US, Europe: Mr Ohyagi  
- Teijin Starts Rental of Small Oxygen Condenser
- 2 Eisai Licenses Kissei's Glufast in ASEAN Countries
- 2 Yakult Aims for ¥33 Bil. Sales by Boosting Sales of Oxaliplatin
- 3 Kirin Aims at 50% Market Share with Nesp
- 3 Zetia Expands Options for Dyslipidemia with New Mechanism of Action: Schering-Plough, Bayer
- 4 Pfizer Japan Invites 600 Employees to Retire
- 4 JPMA Members Should Not Depend on Long-Listed Drugs: President Aoki

- 5 Pfizer Most Active in GP Market: MOSS Survey  
- Takeda Leads in Hospital Market  
- Doctors Want to See Takeda's MRs Most  
- Total Number of Calls per Month

## BUSINESS NEWS IN BRIEF

- 6 - Chugai Stops Shipment of 60-mg Formulation of Herceptin  
- Canadian Court Rules for Daiichi Sankyo in Levofloxacin Patent Dispute

## NEW PRODUCTS

- 6 - Astellas: Selective COX-2 Inhibitor Celecox  
- Pfizer: Somavert to Treat Acromegaly  
- Abilify Tablet 12 mg: Otsuka  
- Benet Tab. 17.5 mg/Actonel Tab. 17.5 mg: Takeda, Ajinomoto/Eisai  
- Kyorin, Ono: Imidafenacin for Overactive Bladder  
- Nihon Schering, Shiseido to Launch l'estrogeol without NHI Price Listing  
- Genzyme Japan: Myozyme for Glycogenosis  
- Maruhō: Oxarol Lotion 25 µg/g for Psoriasis

## REGULATORY

- 8 14 New Kit/Report Products Included in NHI Price List
- 8 JPMA Explains Its Drug Pricing System Reform Proposal to Its Members  
- No Price Cut during Patent Life, 50% Price Cut upon Launching of Generics  
- Companies Should Be Allowed to Price Their Own Products

- JPMA Accepts Yearly NHI Price Revisions  
- Continuous Development of New Drugs Needed
- 10 US Gov't Confirms Opposition to Yearly Revisions of NHI Prices: Policy Initiatives
- 10 Price Gaps between Original Drugs and Generics too Large: Mr Mukai of MOF  
- Elimination of OTC Drug-Like Ethical Drugs to Become Reality in 4 or 5 Years  
- Long-Listed Drug-Dependent Companies to Fail in Several Years: Mr Takeda of *Koroshō*

## REGULATORY NEWS IN BRIEF

- 11 - Study Group to Recommend Approval of Compassionate Use System  
- Use of Methotrexate for JIA Needs Further Discussions: Council  
- 706 Deaths Due to Iressa as of March 2007: *Koroshō*  
- WG to Determine Causal Relation between Sudden Death and Tamiflu

## OPINION

- 12 - Be the First to Know: Philip Carrigan

## R&D

- 14 43rd ASCO Annual Meeting in Chicago

- Sorafenib Increases Overall Survival by 44%  
- Sorafenib Increases PFS in Patients with Advanced Renal Cell Carcinoma

- Temsirolimus Increases Survival Compared to INF- $\alpha$   
- MabThera Extends Survival in Aggressive NHL: Roche

- Tykerb + Paclitaxel Increases PFS in HER-Positive Breast Cancer Patients: GSK

- GEMZAR Effective in Early-Stage Breast Cancer: Eli Lilly

- Erbitux Effective for Colorectal Cancer: Merck  
- Aromasin Reduces Risk of Endometrial Thickening: Pfizer

- Femara Reduces Risk of Recurrence in PgR-Positive Patients as Well: Novartis

- TS-1 + Cisplatin Increases Survival Compared to TS-1 Alone

- Domestic PIII Data on Casodex Cited in ASCO GL e-IND Studies Useful but Problems Need to Be Solved: Symposium

- Major Investment Should Be Made Only after POC Studies: Dr Torii of Janssen

- Conduct POC Studies as Part of Global Development Program: Mr Mori of PMDA

- 18 AMG001's Efficacy for CLI Confirmed in PIII: AnGes MG

- 18 Takeda, Archemix Tie Up for Aptamer Therapeutics

## R&D NEWS IN BRIEF

- 18 - DMARDs + Actemra Combination Improves RA: Roche  
18 - Avastin Prolongs PFS in NSCLC Patients: Roche

## GENERICS

- 19 JGPMA Proposes "Drug Benefit Standard Price" System

## GENERIC NEWS IN BRIEF

- 19 - Nippon Kayaku Launches Generic of Kytril  
- Pharmacists' Cooperation Essential to Promote Use of Generics: Mr Chiba  
- Spread of DPC to Accelerate Use of Generics: Prof. Koyama

## Commentary

- 21 - Generic Firms Need Stronger Business Platform to Ensure Nationwide Stable Supply

## MEDICAL DEVICES

## MEDICAL DEVICE NEWS IN BRIEF

- 20 - Asahi Kasei Medical Opens New Training Center  
- Hitachi High-Tech, NCC to Jointly Develop Blood Diagnosis Method  
- BDJ Receives Insurance Coverage for *Gonococcus/Chlamydia* Test

## MEDICAL FACILITIES & NURSING CARE

- 22 Hemorrhoid Recurrence Rate 16% 1 Year after Zione Treatment

## Survey

- 22 - Smoking Rate Drops Below 40% in Men for First Time  
- Non-smokers Reach 88% among New Company Employees  
- Only 3.6% of Smokers Trying to Stop Smoking Receive Treatment: Novartis  
- Smoking Prohibited in Only 30% of Medical Schools, 50% of Univ. Hospitals  
- Psychological Dependence Main Factor Preventing People from Stopping Smoking